Microdosing GLP-1s Like Wegovy, Zepbound May Still Lead to Weight Loss

Research shows that microdosing GLP-1 medications may still lead to weight loss. Tatsiana Volkava · Moment/Getty Recent research suggests that people may still lose weight while staying on the lowest starting doses of GLP-1 medications, such as Wegovy or Zepbound, for longer periods. After one year, people taking sustained low dose tirzepatide lost about 5.5% of their body weight, while those taking sustained low dose semaglutide lost about 2.2%. Lower doses were associated with more modest weight loss than higher doses, but sustained low dose semaglutide was also associated with lower rates of some side effects. People may still be able to experience weight loss by staying on lower starting doses of GLP-1 medications, such as Wegovy or Zepbound, for longer, according to research published in Biology Methods & Protocols on August 31. Staying on lower doses of GLP-1 medications for longer may overlap with a practice commonly referred to as “microdosing,” which has become a trend among celebrities and on social media. However, the study did not establish that participants were intentionally microdosing, and using these medications outside their approved dosing schedules is not FDA- …

≈